Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more
Excelsior Biopharma (6496) - Total Liabilities
Latest total liabilities as of June 2025: NT$520.48 Million TWD
Based on the latest financial reports, Excelsior Biopharma (6496) has total liabilities worth NT$520.48 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Excelsior Biopharma - Total Liabilities Trend (2017–2024)
This chart illustrates how Excelsior Biopharma's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Excelsior Biopharma Competitors by Total Liabilities
The table below lists competitors of Excelsior Biopharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Secuve Co. Ltd
KQ:131090
|
Korea | ₩2.88 Billion |
|
Kentucky First Federal Bancorp
NASDAQ:KFFB
|
USA | $326.18 Million |
|
Yao I Fabric Co Ltd
TWO:4430
|
Taiwan | NT$1.81 Billion |
|
GSE Systems Inc
NASDAQ:GVP
|
USA | $17.55 Million |
|
Norsemont Mining Inc
PINK:NRRSF
|
USA | $5.52 Million |
|
Korea Eng Cons
KO:023350
|
Korea | ₩236.24 Billion |
|
HiTi Digital Inc
TW:3494
|
Taiwan | NT$1.23 Billion |
|
Leclanche S.A. Reg.
LSE:0QP6
|
UK | CHF166.92 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Excelsior Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Excelsior Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Excelsior Biopharma (2017–2024)
The table below shows the annual total liabilities of Excelsior Biopharma from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$586.89 Million | +24.11% |
| 2023-12-31 | NT$472.87 Million | -6.83% |
| 2022-12-31 | NT$507.53 Million | -16.65% |
| 2021-12-31 | NT$608.90 Million | -1.34% |
| 2020-12-31 | NT$617.15 Million | +152.87% |
| 2019-12-31 | NT$244.06 Million | -9.90% |
| 2018-12-31 | NT$270.88 Million | -20.18% |
| 2017-12-31 | NT$339.37 Million | -- |